Cannabis Law Report

JUNE 21, 2021

Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Advantages of Data, Macro, and Micro. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We RADNOR, Pa.–(BUSINESS Additionally, improved developmental outcomes may lead to improved patient quality of life.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Medical Marijuana Program Connection

MARCH 20, 2023

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the. Read More

Pharmaceutical 52

Pharmaceutical Data Therapy Business 52

Cannabis Law Report

JUNE 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. For more information, visit www.mymd.com. About FTSE Russell.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Veriheal

AUGUST 12, 2021

Unlike “pharmaceutical CBD”—which contains zero traces of the psychoactive compound THC (tetrahydrocannabinol) and has been FDA-approved to treat Dravet syndrome and Lennox-Gastaut syndrome —artisanal CBD is non-mechanized and usually contains variable amounts of CBD and THC. It goes by the name of “artisanal CBD.” .

Epilepsy 81

Epilepsy Pharmaceutical Patients Sleep 81

Cannabis Law Report

AUGUST 10, 2021

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Medical Marijuana Program Connection

FEBRUARY 28, 2023

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the. Read More

Pharmaceutical 52

Pharmaceutical Therapy Data Business 52

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JULY 5, 2021

The ERP operates as a system, collecting data in real time and connecting it all together for your. Since the ERP is equipped with all of the company’s information, the access to data is controlled. Since the ERP is equipped with all of the company’s information, the access to data is controlled. Access Control.

Pharmaceutical 111

Pharmaceutical Data Access Business 111

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

DECEMBER 8, 2021

Global Psychiatry Partnering 2014 to 2021 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Access to headline, upfront, milestone and royalty data. Access Psychiatry deal headline, upfront, milestone and royalty data. Admera Health.

Access 52

Access Data Pharmaceutical Research and Development 52

Cannabis Law Report

NOVEMBER 10, 2019

Europe Cannabis and Pain Management Devices on Cancer Pain market by key players: Cannabis Players: GW Pharmaceuticals. UNIMED PHARMACEUTICALS. Valeant Pharmaceuticals. About Us: MarketIntellica is a unique source of market research data for clients that comprise acclaimed SMEs, Chinese companies, private equity firms, and MNCs.

Pharmaceutical 45

Pharmaceutical Research and Development Data Business 45

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 8, 2021

Flora will now have the ability to quickly and efficiently reference and manage information at its cultivation and extraction facility, collect and analyze data, derive insights to find cost efficiencies, and ensure accuracy. MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp. For more information, please visit www.trutrace.co.

Supply Chain 95

Supply Chain Pharmaceutical Seed-To-Sale Events 95

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

NOVEMBER 26, 2021

Jazz Pharmaceuticals Plc. The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. Companies Mentioned. Aurora Cannabis Inc. Bhang Corp. Cannoid LLC. Canopy Growth Corp.

Pharmaceutical 52

Pharmaceutical Legalization Data Decriminalization 52

NORML

MAY 26, 2020

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain.

Clinical Trials 250

Clinical Trials Chronic Pain Cannabinoids Patients 250

NewsMunchies

JULY 10, 2023

AI tools are gaining popularity in biomedical research because while it can take years for the pharmaceutical industry to create medicines capable of treating or curing human disease, using AI could vastly accelerate the drug-development process. AI automation opens up the possibility of faster, cheaper pharmaceuticals.

Treatment 58

Treatment Research and Development Pharmaceutical Microdosing 58

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

MARCH 8, 2023

The partnership will enable Puro to become a data-led cannabis cultivator, streamline its operations & adhere to the highest pharmaceutical standards.

Seed-To-Sale 52

Seed-To-Sale Cultivation Pharmaceutical Data 52

Cannabis Law Report

AUGUST 3, 2021

Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Medxtractor Corp.

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Google Translation.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

JULY 27, 2021

NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S.,

Research and Development 98

Research and Development Pharmaceutical Sativa Extraction 98

Cannabis Law Report

AUGUST 19, 2021

The industrial hemp market is being driven by the rising application of the fibre in various industries, including food and beverage, personal care, pharmaceutical and textiles, among others. 12 Trade Data Analysis (HS Code: 5302). Key Topics Covered: 1 Preface. 2 Report Coverage – Key Segmentation and Scope. 4 Key Assumptions.

Hemp 98

Hemp Research and Development Pharmaceutical Data 98

Veriheal

FEBRUARY 21, 2023

” Restricting qualifying conditions also results in limited data collection, hindering the collective understanding of medical cannabis. Furthermore, Nugg MD’s data shows just how vital MMJ access has become in modern society’s health landscape. Many patients take MMJ for more reasons than one.

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

Cannabis Law Report

AUGUST 29, 2021

The export to Brazil also confirms the regulatory pathway and acts as a proof of concept in the largest market in South America where we aim to establish long-lasting supply relationships with our Brazilian pharmaceutical partners.”. 1 Source: Passport, Euromonitor International, Cannabis in Latin America, July 2021.

Extraction 98

Extraction Supply Chain Research and Development CBD 98

Canna Law Blog

FEBRUARY 25, 2022

If you keep a pulse on this issue, you know that for the past three years, the FDA has held the position that CBD cannot be marketed as a dietary ingredient because it was first studied and approved as a drug ingredient in GW Pharmaceuticals’ Epidiolex ( Drug Exclusion Rule ). According to NPA’s petition, the U.S.

CBD 80

CBD Safety Data Food 80

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

JUNE 5, 2021

” Kulfas’ presentation began with some hard data, giving an account of the importance of regulating the activity in Argentina. Production chains: Medical cannabis (pharmaceuticals, phytotherapeutics, cosmetics) and industrial hemp (textiles, paper, food, construction materials, etc.). ley cáñamo argentina.

Hemp 105

Hemp Research and Development Pharmaceutical Agriculture 105

Cannabis Law Report

AUGUST 27, 2021

Toru Tanaka, chief of the Ministry of Health, Labor and Welfare’s Surveillance and Narcotics Countermeasures Division, said, “In the past, there were cases where surveillance camera data was stored for five years. There are also regulations that are clearly overkill.

Pharmaceutical 98

Pharmaceutical Cultivation Data Policy 98